ZOGENIX INC. overview

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zogenix, Inc. (Nasdaq - ZGNX), Social Capital Suvretta Holdings Corp. III (Nasdaq - DNAC), Viveon Health Acquisition Corp. (NYSE American - VHAQ) PR Newswire BALA CYNWYD, Pa., Jan. 26, 2022 BALA CYNWYD, Pa. , Jan. 26, 2022 /PRNewswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at...

ZOGENIX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zogenix, Inc. - ZGNX PR Newswire NEW ORLEANS, Jan. 20, 2022 NEW ORLEANS , Jan. 20, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Zogenix, Inc. (NASDAQGM: ZGNX) to UCB. Under the terms of the proposed transaction,...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Zogenix, Inc. PR Newswire NEW YORK, Jan. 19, 2022 NEW YORK , Jan. 19, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX), in connection with the proposed acquisition of the Company by UCB S.A. ("UCB") (Euronext: UCB) via a tender offer. Under the terms of the acquisition agreement, the Company's...

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would acquire Zogenix for $26.00 per share in cash, plus a contingent value right for a potential cash payment of $2.00 per share upon EU approval by December 31, 2023, of FINTEPLA®. Halper Sadeh encourages Zogenix shareholders to click here to learn more about their legal rights and options or...

Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies PR Newswire CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 CAMBRIDGE, Mass. and EMERYVILLE, Calif. , Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information...